Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCI-952 tablet formulation pharmacokinetic crossover study in healthy male volunteers
NL-OMON36120Phase 1Active, not recruiting
- Sponsor
- BrainCells Inc.
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buspirone and melatonin in major depressive disorder (MDD), sponsored by BrainCells Inc. Primary endpoints: Pharmacokinetics, Safety and 1 more. Started Apr 2011; status: active, not recruiting.
02
Drugs
buspironemelatonin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON36120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36120.